nodes	percent_of_prediction	percent_of_DWPC	metapath
Losartan—ALB—acquired immunodeficiency syndrome	0.174	1	CbGaD
Losartan—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.0522	0.0859	CbGbCtD
Losartan—UGT2B7—Zidovudine—acquired immunodeficiency syndrome	0.0283	0.0466	CbGbCtD
Losartan—SLC22A6—Stavudine—acquired immunodeficiency syndrome	0.0273	0.045	CbGbCtD
Losartan—SLC22A6—Didanosine—acquired immunodeficiency syndrome	0.0207	0.0341	CbGbCtD
Losartan—SLCO1B1—Indinavir—acquired immunodeficiency syndrome	0.0201	0.0331	CbGbCtD
Losartan—SLCO1B1—Nelfinavir—acquired immunodeficiency syndrome	0.0195	0.0321	CbGbCtD
Losartan—SLCO1B1—Saquinavir—acquired immunodeficiency syndrome	0.0177	0.0291	CbGbCtD
Losartan—SLCO1B1—Ritonavir—acquired immunodeficiency syndrome	0.0177	0.0291	CbGbCtD
Losartan—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0113	0.0187	CbGbCtD
Losartan—SLC22A6—Zidovudine—acquired immunodeficiency syndrome	0.0109	0.0179	CbGbCtD
Losartan—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0103	0.0169	CbGbCtD
Losartan—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0103	0.0169	CbGbCtD
Losartan—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.00986	0.0162	CbGbCtD
Losartan—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.00986	0.0162	CbGbCtD
Losartan—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.00973	0.016	CbGbCtD
Losartan—ALB—Saquinavir—acquired immunodeficiency syndrome	0.00967	0.0159	CbGbCtD
Losartan—ALB—Zidovudine—acquired immunodeficiency syndrome	0.00927	0.0153	CbGbCtD
Losartan—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.00915	0.0151	CbGbCtD
Losartan—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.00898	0.0148	CbGbCtD
Losartan—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.00885	0.0146	CbGbCtD
Losartan—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.00859	0.0141	CbGbCtD
Losartan—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.00844	0.0139	CbGbCtD
Losartan—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.00844	0.0139	CbGbCtD
Losartan—SLC22A6—Lamivudine—acquired immunodeficiency syndrome	0.00842	0.0139	CbGbCtD
Losartan—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.00827	0.0136	CbGbCtD
Losartan—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.00827	0.0136	CbGbCtD
Losartan—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.00809	0.0133	CbGbCtD
Losartan—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00777	0.0128	CbGbCtD
Losartan—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00777	0.0128	CbGbCtD
Losartan—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00763	0.0126	CbGbCtD
Losartan—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00761	0.0125	CbGbCtD
Losartan—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00761	0.0125	CbGbCtD
Losartan—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00747	0.0123	CbGbCtD
Losartan—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00747	0.0123	CbGbCtD
Losartan—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00738	0.0121	CbGbCtD
Losartan—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00717	0.0118	CbGbCtD
Losartan—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00714	0.0117	CbGbCtD
Losartan—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00693	0.0114	CbGbCtD
Losartan—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00688	0.0113	CbGbCtD
Losartan—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00688	0.0113	CbGbCtD
Losartan—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00668	0.011	CbGbCtD
Losartan—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0064	0.0105	CbGbCtD
Losartan—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00627	0.0103	CbGbCtD
Losartan—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00627	0.0103	CbGbCtD
Losartan—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00601	0.00989	CbGbCtD
Losartan—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00594	0.00977	CbGbCtD
Losartan—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00579	0.00952	CbGbCtD
Losartan—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00576	0.00948	CbGbCtD
Losartan—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00576	0.00948	CbGbCtD
Losartan—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00559	0.0092	CbGbCtD
Losartan—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00521	0.00858	CbGbCtD
Losartan—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00521	0.00858	CbGbCtD
Losartan—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00506	0.00832	CbGbCtD
Losartan—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00506	0.00832	CbGbCtD
Losartan—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.005	0.00822	CbGbCtD
Losartan—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00485	0.00798	CbGbCtD
Losartan—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0047	0.00774	CbGbCtD
Losartan—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00442	0.00728	CbGbCtD
Losartan—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00442	0.00728	CbGbCtD
Losartan—ACE—Metabolism of Angiotensinogen to Angiotensins—ENPEP—acquired immunodeficiency syndrome	0.00407	0.262	CbGpPWpGaD
Losartan—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.004	0.00658	CbGbCtD
Losartan—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.004	0.00658	CbGbCtD
Losartan—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00375	0.00617	CbGbCtD
Losartan—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00345	0.00568	CbGbCtD
Losartan—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00335	0.00551	CbGbCtD
Losartan—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00303	0.00499	CbGbCtD
Losartan—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00303	0.00499	CbGbCtD
Losartan—UGT2B17—digestive system—acquired immunodeficiency syndrome	0.00294	0.0725	CbGeAlD
Losartan—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00291	0.00478	CbGbCtD
Losartan—SLC22A12—digestive system—acquired immunodeficiency syndrome	0.0019	0.0467	CbGeAlD
Losartan—UGT1A10—digestive system—acquired immunodeficiency syndrome	0.00166	0.041	CbGeAlD
Losartan—UGT1A1—blood plasma—acquired immunodeficiency syndrome	0.00149	0.0366	CbGeAlD
Losartan—AGTR1—endothelium—acquired immunodeficiency syndrome	0.00146	0.036	CbGeAlD
Losartan—AGTR1—blood plasma—acquired immunodeficiency syndrome	0.0013	0.032	CbGeAlD
Losartan—ACE—nerve—acquired immunodeficiency syndrome	0.00127	0.0312	CbGeAlD
Losartan—SLC2A9—blood—acquired immunodeficiency syndrome	0.00124	0.0306	CbGeAlD
Losartan—SLCO1B1—blood plasma—acquired immunodeficiency syndrome	0.00124	0.0305	CbGeAlD
Losartan—UGT1A3—digestive system—acquired immunodeficiency syndrome	0.00117	0.0289	CbGeAlD
Losartan—SLC2A9—lung—acquired immunodeficiency syndrome	0.00109	0.0268	CbGeAlD
Losartan—ACE—endothelium—acquired immunodeficiency syndrome	0.00108	0.0266	CbGeAlD
Losartan—ACE—Peptide hormone metabolism—ENPEP—acquired immunodeficiency syndrome	0.00107	0.0689	CbGpPWpGaD
Losartan—ACE—blood plasma—acquired immunodeficiency syndrome	0.000958	0.0236	CbGeAlD
Losartan—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000806	0.0199	CbGeAlD
Losartan—SLC2A9—lymph node—acquired immunodeficiency syndrome	0.000744	0.0183	CbGeAlD
Losartan—SLCO1B3—vagina—acquired immunodeficiency syndrome	0.000727	0.0179	CbGeAlD
Losartan—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000704	0.0173	CbGeAlD
Losartan—SLCO1B3—lung—acquired immunodeficiency syndrome	0.000687	0.0169	CbGeAlD
Losartan—UGT2B7—digestive system—acquired immunodeficiency syndrome	0.000673	0.0166	CbGeAlD
Losartan—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000659	0.0162	CbGeAlD
Losartan—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000635	0.0157	CbGeAlD
Losartan—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000625	0.0154	CbGeAlD
Losartan—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.000572	0.0141	CbGeAlD
Losartan—UGT1A1—blood—acquired immunodeficiency syndrome	0.000545	0.0134	CbGeAlD
Losartan—AGTR1—lymphoid tissue—acquired immunodeficiency syndrome	0.000505	0.0125	CbGeAlD
Losartan—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000477	0.0117	CbGeAlD
Losartan—SLCO1B1—digestive system—acquired immunodeficiency syndrome	0.000476	0.0117	CbGeAlD
Losartan—AGTR1—blood—acquired immunodeficiency syndrome	0.000476	0.0117	CbGeAlD
Losartan—SLCO1B1—blood—acquired immunodeficiency syndrome	0.000453	0.0112	CbGeAlD
Losartan—AGTR1—vagina—acquired immunodeficiency syndrome	0.000441	0.0109	CbGeAlD
Losartan—AGTR1—lung—acquired immunodeficiency syndrome	0.000417	0.0103	CbGeAlD
Losartan—AGTR1—nervous system—acquired immunodeficiency syndrome	0.000386	0.00951	CbGeAlD
Losartan—SLCO1B3—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000376	0.0243	CbGpPWpGaD
Losartan—ACE—lymphoid tissue—acquired immunodeficiency syndrome	0.000373	0.00919	CbGeAlD
Losartan—AGTR1—central nervous system—acquired immunodeficiency syndrome	0.000372	0.00916	CbGeAlD
Losartan—ACE—digestive system—acquired immunodeficiency syndrome	0.000369	0.00908	CbGeAlD
Losartan—AGTR1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000366	0.0236	CbGpPWpGaD
Losartan—SLC22A6—brain—acquired immunodeficiency syndrome	0.000365	0.009	CbGeAlD
Losartan—ACE—blood—acquired immunodeficiency syndrome	0.000351	0.00865	CbGeAlD
Losartan—ACE—bone marrow—acquired immunodeficiency syndrome	0.00034	0.00837	CbGeAlD
Losartan—ACE—spinal cord—acquired immunodeficiency syndrome	0.000338	0.00834	CbGeAlD
Losartan—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000337	0.00831	CbGeAlD
Losartan—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.00031	0.00764	CbGeAlD
Losartan—ACE—lung—acquired immunodeficiency syndrome	0.000308	0.00758	CbGeAlD
Losartan—CYP2C19—blood—acquired immunodeficiency syndrome	0.000295	0.00728	CbGeAlD
Losartan—AGTR1—brain—acquired immunodeficiency syndrome	0.000295	0.00727	CbGeAlD
Losartan—AGTR1—lymph node—acquired immunodeficiency syndrome	0.000285	0.00703	CbGeAlD
Losartan—ACE—nervous system—acquired immunodeficiency syndrome	0.000285	0.00702	CbGeAlD
Losartan—AGTR1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000284	0.0183	CbGpPWpGaD
Losartan—SLCO1B3—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.000279	0.018	CbGpPWpGaD
Losartan—ACE—central nervous system—acquired immunodeficiency syndrome	0.000274	0.00676	CbGeAlD
Losartan—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000274	0.00675	CbGeAlD
Losartan—ALB—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.000273	0.0176	CbGpPWpGaD
Losartan—CYP2C8—blood—acquired immunodeficiency syndrome	0.000258	0.00635	CbGeAlD
Losartan—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000253	0.00624	CbGeAlD
Losartan—SLCO1B1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000253	0.0163	CbGpPWpGaD
Losartan—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000244	0.00602	CbGeAlD
Losartan—CYP1A2—blood—acquired immunodeficiency syndrome	0.000241	0.00594	CbGeAlD
Losartan—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.00024	0.00592	CbGeAlD
Losartan—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000239	0.00589	CbGeAlD
Losartan—CYP3A5—blood—acquired immunodeficiency syndrome	0.000233	0.00573	CbGeAlD
Losartan—CYP2C9—blood—acquired immunodeficiency syndrome	0.000229	0.00564	CbGeAlD
Losartan—ALB—brain—acquired immunodeficiency syndrome	0.000228	0.00561	CbGeAlD
Losartan—ALB—lymph node—acquired immunodeficiency syndrome	0.00022	0.00542	CbGeAlD
Losartan—ACE—brain—acquired immunodeficiency syndrome	0.000218	0.00537	CbGeAlD
Losartan—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000216	0.00531	CbGeAlD
Losartan—CYP1A2—lung—acquired immunodeficiency syndrome	0.000211	0.00521	CbGeAlD
Losartan—ACE—lymph node—acquired immunodeficiency syndrome	0.000211	0.00519	CbGeAlD
Losartan—AGTR1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000204	0.0132	CbGpPWpGaD
Losartan—CYP3A5—lung—acquired immunodeficiency syndrome	0.000204	0.00503	CbGeAlD
Losartan—ACE—Metabolism of proteins—ENPEP—acquired immunodeficiency syndrome	0.000202	0.013	CbGpPWpGaD
Losartan—AGTR1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000192	0.0124	CbGpPWpGaD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000191	0.0123	CbGpPWpGaD
Losartan—SLCO1B1—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.000187	0.0121	CbGpPWpGaD
Losartan—ABCB1—retina—acquired immunodeficiency syndrome	0.000185	0.00455	CbGeAlD
Losartan—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000183	0.00452	CbGeAlD
Losartan—AGTR1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.000182	0.0118	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—TAT—acquired immunodeficiency syndrome	0.000177	0.0114	CbGpPWpGaD
Losartan—CYP3A4—blood—acquired immunodeficiency syndrome	0.000175	0.0043	CbGeAlD
Losartan—AGTR1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000172	0.0111	CbGpPWpGaD
Losartan—CYP2C8—brain—acquired immunodeficiency syndrome	0.00016	0.00394	CbGeAlD
Losartan—AGTR1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000156	0.01	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00015	0.00968	CbGpPWpGaD
Losartan—SLCO1B3—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.000146	0.0094	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000145	0.00936	CbGpPWpGaD
Losartan—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000142	0.00349	CbGeAlD
Losartan—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.00014	0.009	CbGpPWpGaD
Losartan—AGTR1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.000138	0.00892	CbGpPWpGaD
Losartan—AGTR1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.000138	0.00892	CbGpPWpGaD
Losartan—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000136	0.00336	CbGeAlD
Losartan—AGTR1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.000134	0.00867	CbGpPWpGaD
Losartan—AGTR1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000132	0.0085	CbGpPWpGaD
Losartan—AGTR1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.000131	0.00848	CbGpPWpGaD
Losartan—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000131	0.00324	CbGeAlD
Losartan—ABCB1—digestive system—acquired immunodeficiency syndrome	0.00013	0.0032	CbGeAlD
Losartan—ABCB1—blood—acquired immunodeficiency syndrome	0.000124	0.00305	CbGeAlD
Losartan—Valsartan—ALB—acquired immunodeficiency syndrome	0.000122	1	CrCbGaD
Losartan—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.00012	0.00295	CbGeAlD
Losartan—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000119	0.00293	CbGeAlD
Losartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000116	0.00748	CbGpPWpGaD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000115	0.00744	CbGpPWpGaD
Losartan—ABCB1—vagina—acquired immunodeficiency syndrome	0.000115	0.00282	CbGeAlD
Losartan—ABCB1—lung—acquired immunodeficiency syndrome	0.000108	0.00267	CbGeAlD
Losartan—AGTR1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000106	0.00686	CbGpPWpGaD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000104	0.00673	CbGpPWpGaD
Losartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000103	0.00665	CbGpPWpGaD
Losartan—ABCB1—nervous system—acquired immunodeficiency syndrome	0.0001	0.00247	CbGeAlD
Losartan—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	9.96e-05	0.000616	CcSEcCtD
Losartan—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	9.95e-05	0.000615	CcSEcCtD
Losartan—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	9.93e-05	0.000614	CcSEcCtD
Losartan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	9.92e-05	0.000613	CcSEcCtD
Losartan—Pruritus—Stavudine—acquired immunodeficiency syndrome	9.9e-05	0.000612	CcSEcCtD
Losartan—Asthenia—Abacavir—acquired immunodeficiency syndrome	9.89e-05	0.000612	CcSEcCtD
Losartan—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	9.89e-05	0.000611	CcSEcCtD
Losartan—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	9.87e-05	0.000611	CcSEcCtD
Losartan—Myalgia—Ritonavir—acquired immunodeficiency syndrome	9.86e-05	0.00061	CcSEcCtD
Losartan—Chest pain—Ritonavir—acquired immunodeficiency syndrome	9.86e-05	0.00061	CcSEcCtD
Losartan—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	9.86e-05	0.00061	CcSEcCtD
Losartan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	9.83e-05	0.000608	CcSEcCtD
Losartan—Anaemia—Lamivudine—acquired immunodeficiency syndrome	9.83e-05	0.000608	CcSEcCtD
Losartan—Anxiety—Ritonavir—acquired immunodeficiency syndrome	9.83e-05	0.000608	CcSEcCtD
Losartan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	9.8e-05	0.000606	CcSEcCtD
Losartan—SLC2A9—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	9.8e-05	0.00632	CbGpPWpGaD
Losartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	9.79e-05	0.00632	CbGpPWpGaD
Losartan—Pruritus—Abacavir—acquired immunodeficiency syndrome	9.75e-05	0.000603	CcSEcCtD
Losartan—Fatigue—Indinavir—acquired immunodeficiency syndrome	9.75e-05	0.000603	CcSEcCtD
Losartan—Anorexia—Delavirdine—acquired immunodeficiency syndrome	9.75e-05	0.000603	CcSEcCtD
Losartan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	9.75e-05	0.000603	CcSEcCtD
Losartan—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	9.74e-05	0.000602	CcSEcCtD
Losartan—Cough—Saquinavir—acquired immunodeficiency syndrome	9.73e-05	0.000602	CcSEcCtD
Losartan—Angioedema—Lamivudine—acquired immunodeficiency syndrome	9.72e-05	0.000601	CcSEcCtD
Losartan—Constipation—Indinavir—acquired immunodeficiency syndrome	9.67e-05	0.000598	CcSEcCtD
Losartan—Pain—Indinavir—acquired immunodeficiency syndrome	9.67e-05	0.000598	CcSEcCtD
Losartan—Insomnia—Efavirenz—acquired immunodeficiency syndrome	9.67e-05	0.000598	CcSEcCtD
Losartan—Urticaria—Zidovudine—acquired immunodeficiency syndrome	9.66e-05	0.000598	CcSEcCtD
Losartan—ABCB1—central nervous system—acquired immunodeficiency syndrome	9.66e-05	0.00238	CbGeAlD
Losartan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	9.65e-05	0.000597	CcSEcCtD
Losartan—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	9.62e-05	0.000595	CcSEcCtD
Losartan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	9.62e-05	0.000595	CcSEcCtD
Losartan—AGTR1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	9.61e-05	0.0062	CbGpPWpGaD
Losartan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	9.6e-05	0.000594	CcSEcCtD
Losartan—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	9.6e-05	0.000594	CcSEcCtD
Losartan—Malaise—Lamivudine—acquired immunodeficiency syndrome	9.59e-05	0.000593	CcSEcCtD
Losartan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	9.58e-05	0.000592	CcSEcCtD
Losartan—Nausea—Didanosine—acquired immunodeficiency syndrome	9.57e-05	0.000592	CcSEcCtD
Losartan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	9.56e-05	0.000591	CcSEcCtD
Losartan—Hypotension—Delavirdine—acquired immunodeficiency syndrome	9.56e-05	0.000591	CcSEcCtD
Losartan—Syncope—Lamivudine—acquired immunodeficiency syndrome	9.54e-05	0.00059	CcSEcCtD
Losartan—Confusional state—Ritonavir—acquired immunodeficiency syndrome	9.54e-05	0.00059	CcSEcCtD
Losartan—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	9.53e-05	0.000589	CcSEcCtD
Losartan—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	9.52e-05	0.000589	CcSEcCtD
Losartan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	9.5e-05	0.000588	CcSEcCtD
Losartan—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	9.49e-05	0.000587	CcSEcCtD
Losartan—Chest pain—Saquinavir—acquired immunodeficiency syndrome	9.49e-05	0.000587	CcSEcCtD
Losartan—Myalgia—Saquinavir—acquired immunodeficiency syndrome	9.49e-05	0.000587	CcSEcCtD
Losartan—Anxiety—Saquinavir—acquired immunodeficiency syndrome	9.46e-05	0.000585	CcSEcCtD
Losartan—Oedema—Ritonavir—acquired immunodeficiency syndrome	9.46e-05	0.000585	CcSEcCtD
Losartan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	9.43e-05	0.000583	CcSEcCtD
Losartan—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	9.41e-05	0.000582	CcSEcCtD
Losartan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	9.38e-05	0.00058	CcSEcCtD
Losartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	9.38e-05	0.00605	CbGpPWpGaD
Losartan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	9.35e-05	0.000578	CcSEcCtD
Losartan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	9.32e-05	0.000577	CcSEcCtD
Losartan—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	9.32e-05	0.000576	CcSEcCtD
Losartan—Shock—Ritonavir—acquired immunodeficiency syndrome	9.3e-05	0.000575	CcSEcCtD
Losartan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	9.29e-05	0.000575	CcSEcCtD
Losartan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	9.29e-05	0.000574	CcSEcCtD
Losartan—Cough—Lamivudine—acquired immunodeficiency syndrome	9.28e-05	0.000574	CcSEcCtD
Losartan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	9.28e-05	0.000574	CcSEcCtD
Losartan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	9.27e-05	0.000574	CcSEcCtD
Losartan—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	9.26e-05	0.000573	CcSEcCtD
Losartan—Dizziness—Stavudine—acquired immunodeficiency syndrome	9.25e-05	0.000572	CcSEcCtD
Losartan—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	9.25e-05	0.000572	CcSEcCtD
Losartan—Insomnia—Delavirdine—acquired immunodeficiency syndrome	9.25e-05	0.000572	CcSEcCtD
Losartan—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	9.23e-05	0.000571	CcSEcCtD
Losartan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	9.22e-05	0.00057	CcSEcCtD
Losartan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	9.21e-05	0.00057	CcSEcCtD
Losartan—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	9.18e-05	0.000568	CcSEcCtD
Losartan—Confusional state—Saquinavir—acquired immunodeficiency syndrome	9.18e-05	0.000568	CcSEcCtD
Losartan—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	9.14e-05	0.000565	CcSEcCtD
Losartan—Constipation—Efavirenz—acquired immunodeficiency syndrome	9.14e-05	0.000565	CcSEcCtD
Losartan—Pain—Efavirenz—acquired immunodeficiency syndrome	9.14e-05	0.000565	CcSEcCtD
Losartan—Rash—Nevirapine—acquired immunodeficiency syndrome	9.14e-05	0.000565	CcSEcCtD
Losartan—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	9.13e-05	0.000565	CcSEcCtD
Losartan—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	9.12e-05	0.000564	CcSEcCtD
Losartan—Dizziness—Abacavir—acquired immunodeficiency syndrome	9.12e-05	0.000564	CcSEcCtD
Losartan—Oedema—Saquinavir—acquired immunodeficiency syndrome	9.1e-05	0.000563	CcSEcCtD
Losartan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	9.09e-05	0.000562	CcSEcCtD
Losartan—Headache—Nevirapine—acquired immunodeficiency syndrome	9.08e-05	0.000562	CcSEcCtD
Losartan—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	9.06e-05	0.00056	CcSEcCtD
Losartan—Chest pain—Lamivudine—acquired immunodeficiency syndrome	9.06e-05	0.00056	CcSEcCtD
Losartan—Myalgia—Lamivudine—acquired immunodeficiency syndrome	9.06e-05	0.00056	CcSEcCtD
Losartan—Infection—Saquinavir—acquired immunodeficiency syndrome	9.04e-05	0.000559	CcSEcCtD
Losartan—AGTR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	9.04e-05	0.00583	CbGpPWpGaD
Losartan—AGTR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	9.04e-05	0.00583	CbGpPWpGaD
Losartan—Anxiety—Lamivudine—acquired immunodeficiency syndrome	9.03e-05	0.000558	CcSEcCtD
Losartan—Anorexia—Ritonavir—acquired immunodeficiency syndrome	9.01e-05	0.000558	CcSEcCtD
Losartan—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	9e-05	0.000557	CcSEcCtD
Losartan—Urticaria—Indinavir—acquired immunodeficiency syndrome	8.99e-05	0.000556	CcSEcCtD
Losartan—SLC22A12—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	8.96e-05	0.00578	CbGpPWpGaD
Losartan—Shock—Saquinavir—acquired immunodeficiency syndrome	8.96e-05	0.000554	CcSEcCtD
Losartan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	8.95e-05	0.000553	CcSEcCtD
Losartan—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	8.94e-05	0.000553	CcSEcCtD
Losartan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.94e-05	0.000553	CcSEcCtD
Losartan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.93e-05	0.000552	CcSEcCtD
Losartan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.93e-05	0.000552	CcSEcCtD
Losartan—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.91e-05	0.000551	CcSEcCtD
Losartan—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.9e-05	0.00055	CcSEcCtD
Losartan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	8.89e-05	0.00055	CcSEcCtD
Losartan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	8.86e-05	0.000548	CcSEcCtD
Losartan—Rash—Nelfinavir—acquired immunodeficiency syndrome	8.85e-05	0.000547	CcSEcCtD
Losartan—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	8.84e-05	0.000547	CcSEcCtD
Losartan—Hypotension—Ritonavir—acquired immunodeficiency syndrome	8.84e-05	0.000547	CcSEcCtD
Losartan—Rash—Stavudine—acquired immunodeficiency syndrome	8.82e-05	0.000546	CcSEcCtD
Losartan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	8.82e-05	0.000545	CcSEcCtD
Losartan—Dermatitis—Stavudine—acquired immunodeficiency syndrome	8.82e-05	0.000545	CcSEcCtD
Losartan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	8.81e-05	0.000545	CcSEcCtD
Losartan—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	8.8e-05	0.000544	CcSEcCtD
Losartan—Headache—Nelfinavir—acquired immunodeficiency syndrome	8.79e-05	0.000544	CcSEcCtD
Losartan—AGTR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	8.79e-05	0.00567	CbGpPWpGaD
Losartan—Headache—Stavudine—acquired immunodeficiency syndrome	8.77e-05	0.000542	CcSEcCtD
Losartan—Vomiting—Abacavir—acquired immunodeficiency syndrome	8.77e-05	0.000542	CcSEcCtD
Losartan—Confusional state—Lamivudine—acquired immunodeficiency syndrome	8.76e-05	0.000541	CcSEcCtD
Losartan—Pain—Delavirdine—acquired immunodeficiency syndrome	8.75e-05	0.000541	CcSEcCtD
Losartan—Constipation—Delavirdine—acquired immunodeficiency syndrome	8.75e-05	0.000541	CcSEcCtD
Losartan—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	8.74e-05	0.000541	CcSEcCtD
Losartan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	8.73e-05	0.00054	CcSEcCtD
Losartan—Rash—Abacavir—acquired immunodeficiency syndrome	8.69e-05	0.000538	CcSEcCtD
Losartan—Dermatitis—Abacavir—acquired immunodeficiency syndrome	8.68e-05	0.000537	CcSEcCtD
Losartan—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	8.68e-05	0.000537	CcSEcCtD
Losartan—Oedema—Lamivudine—acquired immunodeficiency syndrome	8.68e-05	0.000537	CcSEcCtD
Losartan—Anorexia—Saquinavir—acquired immunodeficiency syndrome	8.68e-05	0.000537	CcSEcCtD
Losartan—Headache—Abacavir—acquired immunodeficiency syndrome	8.64e-05	0.000534	CcSEcCtD
Losartan—Infection—Lamivudine—acquired immunodeficiency syndrome	8.63e-05	0.000534	CcSEcCtD
Losartan—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	8.62e-05	0.000533	CcSEcCtD
Losartan—Nausea—Nevirapine—acquired immunodeficiency syndrome	8.61e-05	0.000532	CcSEcCtD
Losartan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	8.61e-05	0.000532	CcSEcCtD
Losartan—Insomnia—Ritonavir—acquired immunodeficiency syndrome	8.55e-05	0.000529	CcSEcCtD
Losartan—Shock—Lamivudine—acquired immunodeficiency syndrome	8.54e-05	0.000528	CcSEcCtD
Losartan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	8.52e-05	0.000527	CcSEcCtD
Losartan—Hypotension—Saquinavir—acquired immunodeficiency syndrome	8.51e-05	0.000526	CcSEcCtD
Losartan—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	8.5e-05	0.000526	CcSEcCtD
Losartan—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	8.49e-05	0.000525	CcSEcCtD
Losartan—Urticaria—Efavirenz—acquired immunodeficiency syndrome	8.49e-05	0.000525	CcSEcCtD
Losartan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	8.45e-05	0.000523	CcSEcCtD
Losartan—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	8.45e-05	0.000523	CcSEcCtD
Losartan—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	8.43e-05	0.000521	CcSEcCtD
Losartan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	8.43e-05	0.000521	CcSEcCtD
Losartan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	8.41e-05	0.00052	CcSEcCtD
Losartan—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	8.39e-05	0.000519	CcSEcCtD
Losartan—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	8.36e-05	0.000517	CcSEcCtD
Losartan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	8.34e-05	0.000516	CcSEcCtD
Losartan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	8.33e-05	0.000515	CcSEcCtD
Losartan—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	8.32e-05	0.000515	CcSEcCtD
Losartan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	8.32e-05	0.000515	CcSEcCtD
Losartan—Nausea—Stavudine—acquired immunodeficiency syndrome	8.31e-05	0.000514	CcSEcCtD
Losartan—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	8.29e-05	0.000513	CcSEcCtD
Losartan—Anorexia—Lamivudine—acquired immunodeficiency syndrome	8.28e-05	0.000512	CcSEcCtD
Losartan—Insomnia—Saquinavir—acquired immunodeficiency syndrome	8.23e-05	0.000509	CcSEcCtD
Losartan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	8.22e-05	0.000508	CcSEcCtD
Losartan—Nausea—Abacavir—acquired immunodeficiency syndrome	8.19e-05	0.000506	CcSEcCtD
Losartan—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	8.17e-05	0.000505	CcSEcCtD
Losartan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	8.15e-05	0.000504	CcSEcCtD
Losartan—AGTR1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	8.13e-05	0.00524	CbGpPWpGaD
Losartan—Urticaria—Delavirdine—acquired immunodeficiency syndrome	8.12e-05	0.000502	CcSEcCtD
Losartan—Asthenia—Indinavir—acquired immunodeficiency syndrome	8.12e-05	0.000502	CcSEcCtD
Losartan—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	8.11e-05	0.000502	CcSEcCtD
Losartan—Hypotension—Lamivudine—acquired immunodeficiency syndrome	8.11e-05	0.000502	CcSEcCtD
Losartan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	8.09e-05	0.0005	CcSEcCtD
Losartan—Pain—Ritonavir—acquired immunodeficiency syndrome	8.09e-05	0.0005	CcSEcCtD
Losartan—Constipation—Ritonavir—acquired immunodeficiency syndrome	8.09e-05	0.0005	CcSEcCtD
Losartan—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	8.08e-05	0.0005	CcSEcCtD
Losartan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	8.08e-05	0.0005	CcSEcCtD
Losartan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	8.04e-05	0.000497	CcSEcCtD
Losartan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	8.02e-05	0.00517	CbGpPWpGaD
Losartan—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	8.01e-05	0.000496	CcSEcCtD
Losartan—Pruritus—Indinavir—acquired immunodeficiency syndrome	8e-05	0.000495	CcSEcCtD
Losartan—AGTR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	7.95e-05	0.00513	CbGpPWpGaD
Losartan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.91e-05	0.000489	CcSEcCtD
Losartan—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	7.91e-05	0.000489	CcSEcCtD
Losartan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	7.87e-05	0.000487	CcSEcCtD
Losartan—Insomnia—Lamivudine—acquired immunodeficiency syndrome	7.85e-05	0.000486	CcSEcCtD
Losartan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.85e-05	0.000485	CcSEcCtD
Losartan—SLCO1B3—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.81e-05	0.00504	CbGpPWpGaD
Losartan—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	7.8e-05	0.000482	CcSEcCtD
Losartan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	7.79e-05	0.000482	CcSEcCtD
Losartan—Constipation—Saquinavir—acquired immunodeficiency syndrome	7.78e-05	0.000481	CcSEcCtD
Losartan—Pain—Saquinavir—acquired immunodeficiency syndrome	7.78e-05	0.000481	CcSEcCtD
Losartan—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	7.74e-05	0.000479	CcSEcCtD
Losartan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	7.74e-05	0.000479	CcSEcCtD
Losartan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	7.73e-05	0.000478	CcSEcCtD
Losartan—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	7.73e-05	0.000478	CcSEcCtD
Losartan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	7.72e-05	0.000477	CcSEcCtD
Losartan—ABCB1—brain—acquired immunodeficiency syndrome	7.67e-05	0.00189	CbGeAlD
Losartan—Rash—Zidovudine—acquired immunodeficiency syndrome	7.67e-05	0.000474	CcSEcCtD
Losartan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	7.67e-05	0.000474	CcSEcCtD
Losartan—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	7.66e-05	0.000474	CcSEcCtD
Losartan—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	7.64e-05	0.000473	CcSEcCtD
Losartan—Headache—Zidovudine—acquired immunodeficiency syndrome	7.62e-05	0.000471	CcSEcCtD
Losartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	7.59e-05	0.00489	CbGpPWpGaD
Losartan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	7.56e-05	0.000468	CcSEcCtD
Losartan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	7.55e-05	0.000467	CcSEcCtD
Losartan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	7.53e-05	0.000466	CcSEcCtD
Losartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	7.53e-05	0.00485	CbGpPWpGaD
Losartan—Urticaria—Ritonavir—acquired immunodeficiency syndrome	7.51e-05	0.000465	CcSEcCtD
Losartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	7.51e-05	0.00484	CbGpPWpGaD
Losartan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	7.5e-05	0.000464	CcSEcCtD
Losartan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	7.49e-05	0.000463	CcSEcCtD
Losartan—Dizziness—Indinavir—acquired immunodeficiency syndrome	7.48e-05	0.000463	CcSEcCtD
Losartan—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	7.48e-05	0.000462	CcSEcCtD
Losartan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	7.48e-05	0.000462	CcSEcCtD
Losartan—AGTR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	7.45e-05	0.0048	CbGpPWpGaD
Losartan—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	7.44e-05	0.00046	CcSEcCtD
Losartan—Pain—Lamivudine—acquired immunodeficiency syndrome	7.43e-05	0.000459	CcSEcCtD
Losartan—Constipation—Lamivudine—acquired immunodeficiency syndrome	7.43e-05	0.000459	CcSEcCtD
Losartan—ABCB1—lymph node—acquired immunodeficiency syndrome	7.41e-05	0.00183	CbGeAlD
Losartan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	7.34e-05	0.000454	CcSEcCtD
Losartan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	7.31e-05	0.000452	CcSEcCtD
Losartan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	7.24e-05	0.000447	CcSEcCtD
Losartan—Urticaria—Saquinavir—acquired immunodeficiency syndrome	7.23e-05	0.000447	CcSEcCtD
Losartan—Nausea—Zidovudine—acquired immunodeficiency syndrome	7.23e-05	0.000447	CcSEcCtD
Losartan—AGTR1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	7.22e-05	0.00466	CbGpPWpGaD
Losartan—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	7.2e-05	0.000445	CcSEcCtD
Losartan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	7.2e-05	0.000445	CcSEcCtD
Losartan—Vomiting—Indinavir—acquired immunodeficiency syndrome	7.19e-05	0.000445	CcSEcCtD
Losartan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	7.16e-05	0.000443	CcSEcCtD
Losartan—Rash—Indinavir—acquired immunodeficiency syndrome	7.13e-05	0.000441	CcSEcCtD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	7.13e-05	0.0046	CbGpPWpGaD
Losartan—Dermatitis—Indinavir—acquired immunodeficiency syndrome	7.13e-05	0.000441	CcSEcCtD
Losartan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	7.12e-05	0.00459	CbGpPWpGaD
Losartan—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	7.1e-05	0.000439	CcSEcCtD
Losartan—Headache—Indinavir—acquired immunodeficiency syndrome	7.09e-05	0.000438	CcSEcCtD
Losartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	7.08e-05	0.00456	CbGpPWpGaD
Losartan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	7.07e-05	0.000437	CcSEcCtD
Losartan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	7e-05	0.000433	CcSEcCtD
Losartan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	6.97e-05	0.000431	CcSEcCtD
Losartan—Urticaria—Lamivudine—acquired immunodeficiency syndrome	6.9e-05	0.000427	CcSEcCtD
Losartan—AGTR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	6.88e-05	0.00444	CbGpPWpGaD
Losartan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.86e-05	0.000425	CcSEcCtD
Losartan—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	6.86e-05	0.000425	CcSEcCtD
Losartan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.8e-05	0.00042	CcSEcCtD
Losartan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.79e-05	0.00042	CcSEcCtD
Losartan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	6.76e-05	0.000418	CcSEcCtD
Losartan—Rash—Efavirenz—acquired immunodeficiency syndrome	6.74e-05	0.000417	CcSEcCtD
Losartan—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.73e-05	0.000416	CcSEcCtD
Losartan—Nausea—Indinavir—acquired immunodeficiency syndrome	6.72e-05	0.000416	CcSEcCtD
Losartan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	6.71e-05	0.000415	CcSEcCtD
Losartan—Headache—Efavirenz—acquired immunodeficiency syndrome	6.7e-05	0.000414	CcSEcCtD
Losartan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	6.69e-05	0.000414	CcSEcCtD
Losartan—ALB—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	6.6e-05	0.00425	CbGpPWpGaD
Losartan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	6.53e-05	0.000404	CcSEcCtD
Losartan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	6.5e-05	0.000402	CcSEcCtD
Losartan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	6.47e-05	0.0004	CcSEcCtD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	6.45e-05	0.00416	CbGpPWpGaD
Losartan—Rash—Delavirdine—acquired immunodeficiency syndrome	6.45e-05	0.000399	CcSEcCtD
Losartan—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	6.44e-05	0.000398	CcSEcCtD
Losartan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	6.44e-05	0.000398	CcSEcCtD
Losartan—Headache—Delavirdine—acquired immunodeficiency syndrome	6.41e-05	0.000396	CcSEcCtD
Losartan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	6.4e-05	0.000396	CcSEcCtD
Losartan—Nausea—Efavirenz—acquired immunodeficiency syndrome	6.35e-05	0.000393	CcSEcCtD
Losartan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	6.25e-05	0.000387	CcSEcCtD
Losartan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	6.23e-05	0.000385	CcSEcCtD
Losartan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	6.23e-05	0.000385	CcSEcCtD
Losartan—AGTR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	6.2e-05	0.004	CbGpPWpGaD
Losartan—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	6.18e-05	0.00399	CbGpPWpGaD
Losartan—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	6.18e-05	0.00399	CbGpPWpGaD
Losartan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	6.14e-05	0.00038	CcSEcCtD
Losartan—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.07e-05	0.000376	CcSEcCtD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	6.06e-05	0.00391	CbGpPWpGaD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	6.06e-05	0.00391	CbGpPWpGaD
Losartan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.02e-05	0.000372	CcSEcCtD
Losartan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.01e-05	0.000372	CcSEcCtD
Losartan—Rash—Ritonavir—acquired immunodeficiency syndrome	5.96e-05	0.000369	CcSEcCtD
Losartan—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.96e-05	0.000368	CcSEcCtD
Losartan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.94e-05	0.000367	CcSEcCtD
Losartan—Headache—Ritonavir—acquired immunodeficiency syndrome	5.92e-05	0.000366	CcSEcCtD
Losartan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.79e-05	0.000358	CcSEcCtD
Losartan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.74e-05	0.000355	CcSEcCtD
Losartan—Rash—Saquinavir—acquired immunodeficiency syndrome	5.74e-05	0.000355	CcSEcCtD
Losartan—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.73e-05	0.000355	CcSEcCtD
Losartan—Headache—Saquinavir—acquired immunodeficiency syndrome	5.7e-05	0.000353	CcSEcCtD
Losartan—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.62e-05	0.000347	CcSEcCtD
Losartan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.52e-05	0.000341	CcSEcCtD
Losartan—Rash—Lamivudine—acquired immunodeficiency syndrome	5.47e-05	0.000339	CcSEcCtD
Losartan—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.47e-05	0.000338	CcSEcCtD
Losartan—Headache—Lamivudine—acquired immunodeficiency syndrome	5.44e-05	0.000336	CcSEcCtD
Losartan—AGTR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.43e-05	0.0035	CbGpPWpGaD
Losartan—Nausea—Saquinavir—acquired immunodeficiency syndrome	5.41e-05	0.000334	CcSEcCtD
Losartan—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	5.35e-05	0.00345	CbGpPWpGaD
Losartan—AGTR1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	5.26e-05	0.00339	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.25e-05	0.00338	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	5.2e-05	0.00335	CbGpPWpGaD
Losartan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	5.19e-05	0.00335	CbGpPWpGaD
Losartan—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.16e-05	0.000319	CcSEcCtD
Losartan—SLC2A9—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.98e-05	0.00321	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.91e-05	0.00317	CbGpPWpGaD
Losartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.85e-05	0.00313	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.62e-05	0.00298	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.62e-05	0.00298	CbGpPWpGaD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.61e-05	0.00298	CbGpPWpGaD
Losartan—SLC22A12—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.55e-05	0.00294	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.51e-05	0.00291	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.4e-05	0.00284	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—TAT—acquired immunodeficiency syndrome	4.34e-05	0.0028	CbGpPWpGaD
Losartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.16e-05	0.00268	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—TAT—acquired immunodeficiency syndrome	4.09e-05	0.00264	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.08e-05	0.00263	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	4.06e-05	0.00262	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	4.06e-05	0.00262	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	3.95e-05	0.00255	CbGpPWpGaD
Losartan—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	3.86e-05	0.00249	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	3.86e-05	0.00249	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—AGPS—acquired immunodeficiency syndrome	3.69e-05	0.00238	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—TAT—acquired immunodeficiency syndrome	3.69e-05	0.00238	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.51e-05	0.00227	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—AGPS—acquired immunodeficiency syndrome	3.48e-05	0.00224	CbGpPWpGaD
Losartan—AGTR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.16e-05	0.00204	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	3.14e-05	0.00203	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—AGPS—acquired immunodeficiency syndrome	3.14e-05	0.00202	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—ALB—acquired immunodeficiency syndrome	3.08e-05	0.00199	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.02e-05	0.00194	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—TAT—acquired immunodeficiency syndrome	3e-05	0.00193	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3e-05	0.00193	CbGpPWpGaD
Losartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3e-05	0.00193	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	2.94e-05	0.00189	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	2.79e-05	0.0018	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.79e-05	0.0018	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.78e-05	0.00179	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—TAT—acquired immunodeficiency syndrome	2.75e-05	0.00177	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.69e-05	0.00174	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.66e-05	0.00172	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.66e-05	0.00172	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.61e-05	0.00168	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.61e-05	0.00168	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	2.61e-05	0.00168	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.55e-05	0.00164	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.52e-05	0.00163	CbGpPWpGaD
Losartan—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	2.5e-05	0.00161	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	2.5e-05	0.00161	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.45e-05	0.00158	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.41e-05	0.00155	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	2.39e-05	0.00154	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.37e-05	0.00153	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.37e-05	0.00153	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.34e-05	0.00151	CbGpPWpGaD
Losartan—SLC22A6—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.21e-05	0.00143	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	2.12e-05	0.00137	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.1e-05	0.00135	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.04e-05	0.00131	CbGpPWpGaD
Losartan—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.02e-05	0.0013	CbGpPWpGaD
Losartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.01e-05	0.0013	CbGpPWpGaD
Losartan—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.01e-05	0.0013	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.99e-05	0.00128	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.96e-05	0.00126	CbGpPWpGaD
Losartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.91e-05	0.00123	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	1.9e-05	0.00123	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	1.9e-05	0.00123	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	1.82e-05	0.00118	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.8e-05	0.00116	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.79e-05	0.00115	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.00115	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.65e-05	0.00106	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.64e-05	0.00106	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.62e-05	0.00105	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.62e-05	0.00104	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.6e-05	0.00103	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	1.58e-05	0.00102	CbGpPWpGaD
Losartan—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	1.57e-05	0.00101	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	1.55e-05	0.001	CbGpPWpGaD
Losartan—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.54e-05	0.000996	CbGpPWpGaD
Losartan—SLCO1B3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.52e-05	0.000982	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.49e-05	0.00096	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.41e-05	0.000909	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.4e-05	0.000903	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.4e-05	0.000903	CbGpPWpGaD
Losartan—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.38e-05	0.000887	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	1.34e-05	0.000866	CbGpPWpGaD
Losartan—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.34e-05	0.000861	CbGpPWpGaD
Losartan—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.32e-05	0.000854	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.3e-05	0.000841	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.29e-05	0.000829	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.2e-05	0.000773	CbGpPWpGaD
Losartan—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.17e-05	0.000755	CbGpPWpGaD
Losartan—SLC22A6—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.12e-05	0.000725	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.1e-05	0.000708	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.09e-05	0.000705	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.08e-05	0.000694	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.06e-05	0.000687	CbGpPWpGaD
Losartan—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.06e-05	0.000685	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.05e-05	0.000677	CbGpPWpGaD
Losartan—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.04e-05	0.000668	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.03e-05	0.000666	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.02e-05	0.00066	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.59e-06	0.000619	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.38e-06	0.000605	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	9.34e-06	0.000602	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	8.48e-06	0.000547	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	7.62e-06	0.000491	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—ALB—acquired immunodeficiency syndrome	7.57e-06	0.000488	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	7.21e-06	0.000465	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—ALB—acquired immunodeficiency syndrome	7.13e-06	0.00046	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—ALB—acquired immunodeficiency syndrome	6.44e-06	0.000415	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.18e-06	0.000399	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.54e-06	0.000358	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.52e-06	0.000356	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.52e-06	0.000356	CbGpPWpGaD
Losartan—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	5.48e-06	0.000353	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	5.23e-06	0.000337	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.12e-06	0.00033	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.03e-06	0.000325	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—ALB—acquired immunodeficiency syndrome	4.79e-06	0.000309	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.3e-06	0.000277	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.26e-06	0.00021	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	3.18e-06	0.000205	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	2.75e-06	0.000178	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	2.46e-06	0.000159	CbGpPWpGaD
Losartan—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.4e-06	0.000155	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.24e-06	0.000145	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.92e-06	0.000124	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.48e-06	9.53e-05	CbGpPWpGaD
